Skip to main content
Take the Quiz

Proven, respected, doctor recommended

Trusted neurologists from around the country have recommended Boston Scientific Deep Brain Stimulation (DBS) for treatment of Parkinson’s disease (PD). They believe in the results and the science behind our systems.

Hear from an expert

Dr. Jerold Vitek, Professor and Chair, Department of Neurology, University of Minnesota, talks about the difference of the Vercise™ DBS System.

How effective is DBS?

Not all people experience PD the same way or at the same progression. The severity, type, and recurrence of any symptom will vary from person to person—as will their response to DBS treatment. In general, DBS allows people living with PD to decrease their medications and experience fewer side effects, such as uncontrolled movements, incontinence, and moodiness.1

96% Patient Satisfaction

If given the chance, 96% of DBS patients would choose to do it again.2

More “ON Time”

DBS provides an additional 6 hours of "ON time" without troublesome dyskinesias compared to medication alone, giving people more control and independence to live life without rigidity or freezing.3

Sustained Results

Marked improvements in motor function are sustained for at least 5 years.4

Less Tremors

People with tremors experience an average of 70% reduction in tremors, depending on its type of location.5

Fewer Pills

One year after DBS, 75% of people reported a decrease in their Parkinson’s medication.6

Clinical evidence

At Boston Scientifc, it’s important we put our technology to the test. To do this, we conducted a multicenter, prospective, double blinded, randomized, trial for DBS, conducted at one-year follow-up appointments, called the INTREPID study.3

One year into treatment, those who used a Boston Scientific DBS System experienced a 51% improvement in their motor function3

DBS patients who used a Boston Scientific DBS System experienced meaningful improvements in their quality of life3

One year into treatment, Boston Scientific DBS patients experienced a 30% decrease in medication3

Over 90% of subjects and clinicians reported improvement in symptoms at 1 year.7

DBS In Your Daily Life

Join the "Timing is Everything: Your Journey from Diagnosis to DBS" webinar January 14.

Sign up. Stay in. Learn from the comfort of your home.

Learn more

Results from different clinical investigations are not directly comparable. Information provided for educational purposes only.

References: 1. Timmermann L, Jain R, Chen L, et al. Multiple-source current steering in subthalamic nucleus deep brain stimulation for Parkinson’s disease (the VANTAGE study): a non-randomised, prospective, multicentre, open-label study. Lancet Neurol. 2015;14:693-701. doi: 10.1016/S1474-4422(15)00087-3 2. Knoop CD, Kadish R, Hager K, Park MC, Loprinzi PD, LaFaver K. Bridging the gap in patient education for DBS surgery for Parkinson’s disease. Parkinson’s Dis. 2017;2017:9360354. doi:10.1155/2017/9360354 3. Vitek JL, Jain R, Chen L, et al. Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson’s disease (INTREPID): a multicenter, double-blind, randomised, sham-controlled study. Lancet Neurology. 2020;19(6):491‐501. doi:10.1016/S1474-4422(20)30108-3 4. Krack P, Batir A, Van Blercom, N. Five-year follow-up of bilateral stimulation of the subthalmic nucleus in advanced Parkinson’s disease. N Eng J Med. 2003:349(20):1925-1934. doi:10.1056/NEJMoa035275 5. Farris SM, Giroux, ML. (2013). DBS: A Patient Guide to Deep Brain Stimulation. 1st ed. CreateSpace Independent Publishing Platform; 2013. 6. Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: A randomized controlled trial. JAMA. 2009;301(1):63-73. doi:10.1001/jama.2008.929 7. Vitek, J. INTREPID Study. Presented by Robert Gross, Plenary Session, AANS Presented at: 2018 AANS; April 26-27, 2018; New Orleans, Louisiana, USA.

Indication for Use: The Boston Scientific Vercise™ PC, Vercise Gevia™, Vercise Genus™ Deep Brain Stimulation Systems are indicated for use in:
-Bilateral stimulation of the subthalamic nucleus (STN) as an adjunctive therapy in reducing some of the symptoms of moderate to advanced levodopa-responsive Parkinson’s disease (PD) that are not adequately controlled with medication.
-Bilateral stimulation of the internal globus pallidus (GPi) as an adjunctive therapy in reducing some of the symptoms of advanced levodopa-responsive Parkinson’s disease (PD) that are not adequately controlled with medication.
-Unilateral thalamic stimulation of the ventral intermediate nucleus (VIM) is indicated for the suppression of tremor in the upper extremity. The system is intended for use in patients who are diagnosed with essential tremor or parkinsonian tremor not adequately controlled by medications and where the tremor constitutes a significant functional disability. 
-Bilateral stimulation of the ventral intermediate nucleus (VIM) of the thalamus for the suppression of disabling upper extremity tremor in adult essential tremor patients whose tremor is not adequately controlled by medications and where the tremor constitutes a significant functional disability.

The Boston Scientific Vercise Deep Brain Stimulation System is indicated for use in:
-Bilateral stimulation of the subthalamic nucleus (STN) as an adjunctive therapy in reducing some of the symptoms of moderate to advanced levodopa-responsive Parkinson’s disease (PD) that are not adequately controlled with medication.

Contraindications: The Boston Scientific Deep Brain Stimulation (DBS) Systems are not recommended for patients who will be exposed to the following procedures: Diathermy as either a treatment for a medical condition or as part of a surgical procedure, Electroconvulsive Therapy (ECT) and Transcranial Magnetic Stimulation (TMS).  The safety of these therapies in patients implanted with the Boston Scientific DBS System has not been established.  Patients implanted with Boston Scientific DBS Systems without ImageReady™ MRI Technology should not be exposed to Magnetic Resonance Imaging (MRI). Patients implanted with the Vercise Gevia or Vercise Genus or Vercise Genus Mixed System with M8 Adapter or Vercise DBS Lead-Only System (before Stimulator is implanted) with ImageReady MRI Technology are Full Body MR Conditional only when exposed to the MRI environment under the specific conditions defined in ImageReady MRI Guidelines for Boston Scientific DBS Systems.  Boston Scientific DBS Systems are not recommended for patients who are unable to operate the system or are poor surgical candidates or who experience unsuccessful test stimulation.

Warnings: Unauthorized modification to the medical devices is prohibited.  You should not be exposed to high stimulation levels.  High level of stimulation may damage brain tissue.  Patients implanted with a Boston Scientific DBS System may be at risk for intracranial hemorrhages (bleeding in the brain) during DBS lead placement.  Strong electromagnetic fields, such as power generators, security screeners or theft detection systems, can potentially turn the stimulator off, or cause unpredictable changes in stimulation. The system should not be charged while sleeping.  If you notice new onset or worsening depression, changes in mood or behavior or impulse control, or have thoughts of suicide contact your physician or emergency services immediately.  Chemical burns may result if the Stimulator housing is ruptured or pierced.  The Boston Scientific DBS Systems may interfere with the operation of implanted stimulation devices, such as cardiac pacemakers, implanted cardioverter defibrillators, or medication delivery pumps. Patients should operate motorized vehicles or potentially dangerous machinery with caution.  It is unknown if the device may hurt an unborn baby. Your doctor may be able to provide additional information on the Boston Scientific DBS Systems.  For complete indications for use, contraindications, warnings, precautions, and side effects, see DBSandME.com or call 833-DBS-INFO or 833-327-4636.
Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.